Forecast
| Buy |
Â
1 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Virbac exceeds first-half sales forecasts and confirms 2026 targets
In the first half Virbac reported sales of €768m (+7.4% currency-adjusted) and quarterly sales of €384m, slightly above the LSEG consensus estimate of €381m. Growth was driven mainly by volume and product mix (about 5.4 percentage points); price adjustments contributed roughly 2 percentage points. The company confirmed its 2026 targets: sales growth of 5.5–7.5% and an adjusted operating margin of around 17%. » More on de.investing.com
Virbac confirms full-year guidance after 7.7% sales rise in first quarter
Virbac reports currency- and portfolio-adjusted sales growth of 7.7% in Q1, driven by strong North America business (+20.7%) and gains in international markets (+9.1%). Volume increases contributed around 6 percentage points to growth, price adjustments about 2%; exchange rates weighed with roughly -5.5%. The Thyronorm acquisition added about 1%; pet products and livestock showed double-digit and strong increases, while regulatory delays weighed on other businesses. Virbac confirms its full-year guidance of +5.5–7.5% sales growth at constant exchange rates, expects an adjusted EBITA margin of around 17% and cash generation of about €80m with capex of around €125m. » More on de.investing.com
Virbac records 7.9% organic growth in 2025 despite currency headwinds
Virbac reports 2025 revenue of €1,464.7m (+8.7% nominal, +7.9% organic) and adjusted EBIT of €234.4m with a margin of 16.0%. Currency losses weighed on revenue and EBIT, while R&D spending rose to a record level (€115.1m) and the pipeline includes around 40 prioritized projects. North America was the strongest growth region at +14.7%; pets continue to account for the majority of sales (58.8%). The Thyronorm acquisition strengthens the endocrinology platform; management expects 2026 organic revenue growth of 5.5–7.5% and an adjusted EBIT margin of around 17%. » More on de.investing.com
Virbac reports 2025 revenue growth, operational pressures weigh on margins
Virbac posted 2025 revenue of €1,464.7m (+7.9% currency- and portfolio-adjusted) and adjusted EBITA of €234.4m, corresponding to a margin of 16.3%, meeting guidance. Net profit rose 3.2% to €150.5m, while gross margin was hit by 0.7 percentage points due to a temporary halt in antigen production and higher inventory write-downs. R&D spending reached a record level, net debt stood at €172.8m, and a net dividend of €1.45 per share is planned for the annual general meeting. For 2026 Virbac confirms currency- and portfolio-adjusted revenue growth of 5.5–7.5% (including Thyronorm) and targets an adjusted EBITA margin of around 17%; US tariffs have already been factored in. » More on de.investing.com
Virbac soutenu par la recommandation positive d'Oddo BHF
Virbac a enregistré une forte hausse en Bourse après qu'Oddo BHF a relevé sa recommandation de Neutre à Surperformance et augmenté son objectif de cours à 395 euros. Les analystes saluent la solidité des fondamentaux de Virbac et anticipent une amélioration de la marge opérationnelle d'ici 2030. Toutefois, le deuxième trimestre et le premier semestre 2025 seront affectés par une base de comparaison élevée, avec des perspectives plus favorables attendues à partir du troisième trimestre. » More on abcbourse.com
Historical dividends Dividends
All dividend metrics All metricsIn 2026, Virbac has already paid €1.45 in dividends. The last payout was in July.
Financials
In the last quarter, Virbac had revenue of €761.99m and net profit of €86.69m
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 761.99m | - |
| Gross profit | 278.39m | - |
| Net profit | 86.69m | - |
| EBITDA | 165.66m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.93bn |
Number of shares | 8.38m |
52-week high/low | €397.64 - €315.33 |
Dividend yield | 0.41% |
Dividends TTM | €1.45 |
Beta | 0.78 |
P/E ratio | 18.42 |
PEG ratio | 1.08 |
P/B ratio | 2.35 |
P/S ratio | 1.92 |
Company profile
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
| Name | Virbac |
| CEO | Paul Martingell |
| Headquarters | Carros,
pa France |
| Website | |
| IPO | 07/07/1992 |
| Employees | 6,442 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | VIRP.PA |
Pnk | VRBCF |
Frankfurt | V16.F |
DĂĽsseldorf | V16.DU |
London | 0NM7.L |
Paris | VIRP.PA |
MĂĽnchen | V16.MU |
SIX | VIRP.SW |